Manufacturers Life Insurance Company, The Prelude Therapeutics Inc Transaction History

Manufacturers Life Insurance Company, The

$100 Billion
Q1 2025

A detailed history of Manufacturers Life Insurance Company, The transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 69,252 shares of PRLD stock, worth $63,711. This represents 0.0% of its overall portfolio holdings.

Number of Shares

69,252

Previous 70,045 1.13%

Holding current value

$63,711

Previous $88,000 39.77%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$0.64 - $1.39 $507 - $1,102	-793 Reduced 1.13%	69,252 $53,000
Q2 2024 Aug 14, 2024	SELL	$3.32 - $5.63 $7,360 - $12,481	-2,217 Reduced 3.07%	70,045 $266,000
Q1 2024 May 14, 2024	BUY	$2.68 - $4.84 $5,619 - $10,149	2,097 Added 2.99%	72,262 $342,000
Q2 2023 Aug 11, 2023	BUY	$4.45 - $8.12 $159,608 - $291,240	35,867 Added 104.57%	70,165 $315,000
Q4 2022 Aug 11, 2023	BUY	$4.61 - $8.5 $142 - $263	31 Added 0.09%	34,298 $207,000
Q4 2022 Feb 13, 2023	BUY	$4.61 - $8.5 $142 - $263	31 Added 0.09%	34,298 $207,000
Q1 2022 Aug 11, 2023	SELL	$6.9 - $13.22 $213 - $409	-31 Reduced 0.09%	34,267 $236,000
Q1 2022 May 20, 2022	BUY	$6.9 - $13.22 $236,442 - $453,009	34,267 New	34,267 $238,000
Q2 2021 Aug 12, 2021	SELL	$28.63 - $44.3 $157,923 - $244,358	-5,516 Closed	0 $0
Q1 2021 May 03, 2021	BUY	$39.27 - $91.68 $8,914 - $20,811	227 Added 4.29%	5,516 $239,000
Q4 2020 Feb 12, 2021	BUY	$28.81 - $88.94 $152,376 - $470,403	5,289 New	5,289 $378,000

Others Institutions Holding PRLD

# of Institutions

Shares Held

28.3M

Call Options Held

23.9K

Put Options Held

View Full List

About Prelude Therapeutics Inc

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $33.5M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

More about PRLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.

Account

Manufacturers Life Insurance Company, The Prelude Therapeutics Inc Transaction History